Searchable abstracts of presentations at key conferences in endocrinology

ea0084op-03-12 | Oral Session 3: Advanced Thyroid Cancer | ETA2022

Clinicopathological and epidemiological features of thyroid cancer patients intended to initiate systemic therapy

Minaldi Elisa , Esposito Gerardo , Giani Carlotta , Valerio Laura , Agate Laura , Molinaro Eleonora , Elisei Rossella

Objectives: The majority of patients with differentiated thyroid carcinoma (TC) have an excellent prognosis, with a 5-year survival rate of 98.3%, and only rarely reaches an advanced stage of disease. The present study aims to identify the clinicopathological and epidemiological features at the time of diagnosis of a group of patients who required to be treated with systemic therapy with tyrosine-kinase inhibitors (TKI).Methods: We retrospectively evalua...

ea0056p1154 | Thyroid cancer | ECE2018

Circulating thyroid autoantibodies are more sensitive than fine needle aspiration in detecting metastatic thyroid cancer

Ferrari Federica , Agate Laura , Latrofa Francesco

Introduction: Follow up of differentiated thyroid cancer requires periodic measurements of thyroglobulin (Tg) and Tg autoantibodies (TgAb) and neck ultrasound. Recurrence is suspected in presence of rising levels of Tg and/or TgAb. Positive cytology or detectable Tg in washout of fine needle aspiration (FNA) of neck lymph nodes or 131-I neck uptake confirm the diagnosis of metastatic lymph node.Case report: We report on a 25 year-old Caucasian man, affec...

ea0081p638 | Endocrine-Related Cancer | ECE2022

TKI related adverse events in patients with progressive and metastatic thyroid carcinoma: a retrospective analysis of our experience with cabozantinib during EXAM and EXAMINER clinical trial

Cappagli Virginia , Bottici Valeria , Viola David , Agate Laura , Molinaro Eleonora , Elisei Rossella

Background: Vandetanib and Cabozantinib are the only two multitarget tyrosine kinase inhibitors approved for the management of metastatic and progressive medullary thyroid cancer. (MTC) Despite their efficacy in terms of progression free survival prolongation and overall response rate, the drug-related toxicity is still a clinical problem, impairing patient’s quality of life and the compliance to the treatment. We retrospectively evaluate the adverse events (AEs) occurred...

ea0081p472 | Thyroid | ECE2022

Cervical lymph nodes metastases in differentiated thyroid cancer: impact on clinical outcome

Gambale Carla , Matrone Antonio , Contartese Lea , Prete Alessandro , Viola David , Agate Laura , Molinaro Eleonora , Elisei Rossella

Background: Cervical lymph node metastases at histology are common findings in differentiated thyroid cancer (DTC); however, their impact on clinical outcome is debated.Material and method: 1332 DTC patients, performed the first 131 I treatment between January 2010 and September 2012 and were divided into 2 groups: absence (Nx/N0) or presence (N1) of lymph node metastases at histology. The latter group was further split in central compartment ...

ea0084ps2-07-62 | Graves’ Disease 1 | ETA2022

Multifocality in sporadic and familiar medullary thyroid cancer: analysis of prevalence and possible predictive roles

Cappagli Virginia , Bottici Valeria , Agate Laura , Molinaro Eleonora , Torregrossa Liborio , Elisei Rossella

Aims: Surgery is the only curative treatment for medullary thyroid cancer (MTC) patients and the gold standard practice is still represented by total thyroidectomy and prophylactic central neck compartment lymphnode dissection. As it happened for differentiated thyroid cancer, in the last years some authors proposed less aggressive and extent surgical modality as hemithyroidectomy and ipsilateral neck compartment dissection in unilateral and solitary sporadic MTC cases. Few st...

ea0020oc1.1 | Endocrine Tumours | ECE2009

Optimizing time of prophylactic surgery in ret gene carriers on the basis of serum calcitonin

Elisei Rossella , Romei Cristina , Bottici Valeria , Cosci Barbara , Renzini Guilia , Molinaro Eleonora , Agate Laura , Pinchera Aldo

Multiple endocrine neoplasia type 2 (MEN 2) is characterized by the presence of medullary thyroid cancer (MTC) and other benign pathologies. RET mutations are responsible of this disease and their screening is a very sensitive tool for the identification of gene carriers (GC).Aim of this study was to verify the relevance of the basal and pentagastrin (Pg) stimulated serum calcitonin (CT) in the decision to perform TT in GC. We reviewed data of 65 GC foun...

ea0092ps1-06-04 | Thyroid Cancer clinical 1 | ETA2023

Predictive factors for central neck compartment lymphnodes metastases’ in sporadic medullary thyroid cancer patients

Cappagli Virginia , Matrone Antonio , Piaggi Paolo , Bottici Valeria , Agate Laura , Molinaro Eleonora , Torregrossa Liborio , Elisei Rossella

Introduction: Total thyroidectomy (TT) plus central neck compartment (CC) lymphnode dissection is still the recommended initial gold standard treatment for medullary thyroid cancer (MTC), even in the absence of a pre-surgical positive neck US evidence of lymphnode metastases. Considering the risk of surgical complications of this prophylactic surgery and the low rate of histologic finding of CC lymphnode metastases, a more tailored lymphnode’ surgery should be proposed. A...

ea0092ps2-16-04 | Thyroid Cancer clinical 2 | ETA2023

A rare association: graves’s disease and thyroid cancer with hyperfunctioning lung metastasis

Capobianco Martina , Prete Alessandro , Boni Giuseppe , Santini Ferruccio , Elisei Rossella , Latrofa Francesco , Agate Laura

Introduction: The association between thyroid cancer and thyrotoxicosis is rare and, in particular, autonomous hyperfunctioning metastasis of differentiated thyroid cancer (TC) are seldom described, with a prevalence of 0.71%. Althought most hyperfunctioning metastasis are derived from follicular thyroid cancer (FTC), metastasis from papillary thyroid cancer (PTC) have been also reported. Bone metastasis account for the majority of cases. Hyperfunctioning TC metastasis have be...

ea0092ps3-29-01 | Treatment 2 | ETA2023

Impact of local treatments in progressive, advanced, radioiodine-refractory thyroid cancer

Esposito Gerardo , Lorusso Loredana , Minaldi Elisa , bottici valeria , molinaro eleonora , elisei rossella , agate laura

Introduction: The majority of patients with radioiodine-refractory thyroid carcinoma (RAIR-TC) have an indolent disease and require active surveillance (AS) only, while those with progression of the disease (PD) may benefit from local treatment (LT) or systemic therapy with tyrosine-kinase inhibitors (TKI). In the literature, no data about the real impact of LTs in avoiding/delaying systemic treatment in RAIR-TC patients are present.Objective: This study...

ea0084ps1-03-21 | Thyroid Cancer CLINICAL 1 | ETA2022

Risk of structural recurrence in differentiated thyroid carcinoma (DTC) patients without evidence of disease after initial treatment: insights into risk factors and comparison with american thyroid association guidelines

Contartese Lea , Gambale Carla , Prete Alessandro , Puleo Luciana , Cappagli Virginia , Lorusso Loredana , Agate Laura , Molinaro Eleonora , Elisei Rossella , Matrone Antonio

Background: The last American Thyroid Association guidelines (ATA-2015) defined the risk of structural recurrence in patients with DTC cured after initial treatment and according to the initial histology. However, these data resulted from several studies including different patients with different kinds of treatment. We retrospectively evaluated a large population of patients with DTC, treated and followed in a tertiary referral center, with the aim to characterize the rate of...